Compare INSG & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | NBP |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.1M | 173.5M |
| IPO Year | 2000 | N/A |
| Metric | INSG | NBP |
|---|---|---|
| Price | $9.92 | $1.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.33 | $9.00 |
| AVG Volume (30 Days) | 411.6K | ★ 515.3K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | $16.21 | N/A |
| Revenue Next Year | $13.28 | N/A |
| P/E Ratio | $15.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $1.46 |
| 52 Week High | $21.90 | $5.19 |
| Indicator | INSG | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 41.09 |
| Support Level | $9.44 | N/A |
| Resistance Level | $11.81 | $1.67 |
| Average True Range (ATR) | 0.84 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 2.46 | 35.55 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.